"Long-Term Highly Active Anti-Retroviral Therapy in an Anti-Retroviral Experienced Population."

According to an abstract submitted by the authors to the Keystone Symposia HIV Vaccine Development: Opportunities and Challenges and AIDS Pathogenesis, held January 7-13, 1999, in Keystone, Colorado, "To assess the long-term effects of highly active anti-retroviral therapy, we examined 304 anti-retroviral-experienced patients who were placed on HAART for a period of 18 months. The baseline CD4 count was 385x10⁶/1 and HIV RNA level was 3.2 log₁₀ copies/ml. At baseline, 39 percent were classified as asymptomatic, 33 percent were symptomatic, and 28 percent had an AIDS defining illness. The HAART regimens included 3-5 anti-retroviral agents at least one of which was...

Want to see the full article?

• Purchase this article for only $3.00